Walgreens Recalls Cefazolin Infusion Bags Due to Sterility Concerns
Walgreens Infusion Services is recalling Cefazolin in normal saline bags due to a lack of sterility assurance. The products were distributed in six southern states.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a significant hazard like lack of sterility assurance in an injectable drug corresponds to a Severe (4) rating.
Plain-English summary
Walgreens Infusion Services is recalling Cefazolin in various strengths in normal saline bags. The recall was initiated because of a lack of sterility assurance for the products.
The affected products were distributed in Texas, Florida, Virginia, Georgia, Louisiana, and Mississippi. The source text indicates that all products within their expiry dates are included in this recall.
Consumers and healthcare providers should stop using the recalled Cefazolin infusion bags and contact Walgreens Infusion Services for further instructions or a replacement.
The recalled product
- Product
- Cefazolin various strengths in normal saline bags
- Manufacturer
- Walgreens Infusion Services
- Category
- Drug — Antibiotic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All products within expiry.
Distribution
Part of a larger recall action
This product is one of 36 recalled by Walgreens Infusion Services under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 36 products in this recall →Related recalls
Same manufacturer · Walgreens Infusion Services
See all →- SevereWalgreens Recalls IVIG Gamunex Bags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- SevereWalgreens Recalls Cefazolin Infusion Bags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- SevereWalgreens Recalls 0.9% Sodium Chloride/MVI Injection Bags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- SevereWalgreens Infusion Services Recalls Dextrose and Sodium Chloride Injection Bags
FDA (Drugs) · 2016-01-06
- HighWalgreens Recalls Famotidine Injection Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereWalgreens Recalls Cefazolin Infusion Bags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- HighWalgreens Recalls Nafcillin Infusion Bags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- SevereBaptist Health Recalls Cefazolin IV Bags Due to Sterility Concerns
FDA (Drugs) · 2016-06-08
- SevereGuardian Pharmacy Recalls Cefazolin Syringes Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
- SevereWalgreens Recalls Ceftriaxone Minibags Due to Sterility Concerns
FDA (Drugs) · 2016-01-06
- HighCefazolin Antibiotic Injections Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-02-22